Oncology White Papers & Case Studies

  1. SynteractHCR Full-Service CRO Brochure 3/4/2016

    SynteractHCR is a multinational clinical research organization, formed from the merger of Synteract with Harrison Clinical Research in 2013, which provides global, full-service clinical trial services. We have more than two decades of experience supporting biopharma companies in all phases of clinical development across multiple therapeutic areas. We customize programs that will deliver timely, high quality data to help you get to decision points faster, taking time and cost out of drug development.

  2. Research Solutions To Understand Clinical Therapy Market Landscapes 10/6/2015

    Covance was approached by a European client that was considering the acquisition of an early-stage ovarian cancer therapy product.

  3. ECG Assessments During The Development Of Oncology Compounds 8/5/2015

    Assessment of ECGs during the development of oncology compounds is challenging. By THIJS van IERSEL, MD, Clinical Pharmacologist and Senior Director, Global Scientific Affairs, PRA Health Sciences; BORJE DARPO, MD, PhD, Chief Scientific Officer, iCardiac Technologies Inc.; GERD AROLD, MD, Senior Director, Global Scientific Affairs, PRA Health Science

  4. Critical Success Factors For Clinical Trials Of Immune Checkpoint Inhibitors 7/20/2015

    Oncologists and their patients have had reason recently to be encouraged by the launch of immune checkpoint inhibitors (ICIs) for the treatment of several difficult-to-treat diseases, including metastatic melanoma and non-small cell lung cancer. These novel agents activate the human immune response against antigens expressed on tumor cells, and the science has generated excitement among physicians, patients, the media and researchers.

  5. Taking The Guesswork Out Of Feasibility Assessment In Oncology Trials 7/20/2015

    The scientific progress being made in cancer research has never been more encouraging or more rewarding. Yet, virtually all oncology drug sponsors face an uphill battle in what one would expect to be the easiest part of the research process: recruiting patients for clinical trials. Despite the seriousness of the diagnosis—or perhaps because of it—only three percent of adult patients with cancer participate in clinical trials. As a result, under-enrollment is common.

  6. Rare Diseases Clinical Trial Services 12/17/2014

    Clinical development involving rare diseases poses a unique set of medical, scientific, and operational challenges. 

  7. Safety Expertise Leads To FDA Approval For Customer Compound 6/17/2013

    INC Research/inVentiv Health was providing a client with drug safety services for an oncology compound development.

  8. Importance Of Preclinical Imaging In Drug Discovery 5/6/2013

    The process of discovering and bringing a drug to market consists of several stages, beginning with identification and validation of a drug target and continuing through lead identification by high-throughput screening, lead optimization, and profiling in relevant disease models.

  9. Overcoming Clinical Challenges In Oncology With Metabolomics 4/10/2013

    Cancer continues to be a formidable disease with an overall success rate of bringing new drugs to market of only 5-8%.

  10. Leveraging Investigator Grant Payment Practices To Enhance Sponsor-Site Relationships 9/19/2012

    One of the world’s leading pharmaceutical companies, AstraZeneca, has over 67,000 employees. Among those are about 13,000 at 17 principal research and development centers in eight countries — including the United States.